Clinical Study of Kangfuxin Liquid in Adjuvant Anti-Tuberculous Chemotherapy for Intestinal Tuberculosis

ZHANG Min; CHEN Qing; WEI Shuqing; MA Jing; GAO Jintan

doi:10.14009/j.issn.1672-2124.2022.01.006

您当前的位置：

首页 >

文章列表页 >

Clinical Study of Kangfuxin Liquid in Adjuvant Anti-Tuberculous Chemotherapy for Intestinal Tuberculosis

更新时间：2022-10-08

- Clinical Study of Kangfuxin Liquid in Adjuvant Anti-Tuberculous Chemotherapy for Intestinal Tuberculosis
- Vol. 22, Issue 1, Pages: 29-31(2022)
- 作者机构：
  
  河北省胸科医院消化内科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.01.006
  CLC： R524
- Published：2022，
扫描看全文
ZHANG Min, CHEN Qing, WEI Shuqing, et al. Clinical Study of Kangfuxin Liquid in Adjuvant Anti-Tuberculous Chemotherapy for Intestinal Tuberculosis. [J]. 22(1):29-31(2022)
DOI：

ZHANG Min, CHEN Qing, WEI Shuqing, et al. Clinical Study of Kangfuxin Liquid in Adjuvant Anti-Tuberculous Chemotherapy for Intestinal Tuberculosis. [J]. 22(1):29-31(2022) DOI： 10.14009/j.issn.1672-2124.2022.01.006.

摘要

目的:探讨康复新液辅助抗结核化疗方案治疗肠结核的疗效及对炎症因子、T淋巴细胞亚群的影响。方法:选取2018年2月至2019年10月该院收治的肠结核患者92例

随机分为研究组（46例）和对照组（46例）。对照组患者给予常规基础治疗+2HRZE/4HR抗结核化疗方案

研究组患者在对照组的基础上加用康复新液。观察两组患者的临床疗效

并比较两组患者治疗前后炎症因子[肿瘤坏死因子α（TNF-α）、白细胞介素1（IL-1）、白细胞介素10（IL-10）和C反应蛋白（CRP）]水平及T淋巴细胞亚群（CD3

、CD4

、CD8

和CD4

/CD8

）水平变化

记录两组患者不良反应发生情况。结果:研究组患者的总有效率为89.13%（41/46）

显著高于对照组的69.57%（32/46）

差异有统计学意义（P

0.05）。治疗后

两组患者血清TNF-α、IL-1、IL-10、CRP和CD8

水平均较治疗前显著降低

且研究组患者较对照组明显更低

差异均有统计学意义（P

0.05）;治疗后

两组患者CD3

、CD4

和CD4

/CD8

水平均较治疗前显著升高

且研究组患者较对照组明显更高

差异均有统计学意义（P

0.05）。研究组、对照组患者的总不良反应发生率分别为32.61%（15/46）、28.26%（13/46）

差异无统计学意义（χ

=0.205

P=0.650）。结论:采用康复新液辅助抗结核化疗方案治疗肠结核

可显著降低患者机体炎症因子水平

改善细胞免疫系统

提高临床效果

且安全性较好。

Abstract

OBJECTIVE: To probe into the efficacy of Kangfuxin liquid in adjuvant anti-tuberculous chemotherapy for intestinal tuberculosis and its effects on inflammatory factors and T-lymphocyte subsets. METHODS: Totally 92 patients with intestinal tuberculosis admitted into this hospital from Feb. 2018 to Oct. 2019 were extracted to be randomly divided into the study group（ n = 46） and the control group（ n = 46）. The control group was given conventional basic treatment + 2 HRZE/4 HR anti-tuberculosis chemotherapy regimen

while the study group received Kangfuxin liquid on the basis of the control group. The clinical efficacy of two groups were compared

and the changes of levels of inflammatory factors [tumor necrosis factor-α（ TNF-α）

interleukin-1（ IL-1）

interleukin-10（ IL-10）

Creactive protein（ CRP） ] and T lymphocyte subsets（ CD3

CD4

CD8

CD4

/CD8

） before and after treatment were compared between two groups. Adverse drug reactions of two groups were compared. RESULTS: The total effective rate in the study group was 89. 13%（ 41/46）

significantly higher than 69. 57%（ 32/46） in the control group

the difference was statistically significant（ P

0. 05）. After treatment

the levels of TNF-α

IL-1

IL-10

CRP and CD8

in two groups were significantly lower than those before treatment

and the study group was significantly lower than the control group

with statistically significant differences（ P

0. 05）. After treatment

the levels of CD3

CD4

and CD4

/CD8

in two groups were significantly higher than those before treatment

and the study group was higher than the control group

the differences were statistically significant（ P

0. 05）. The incidence of total adverse drug reactions in the study group and the control group were respectively 32. 61%（ 15/46） and 28. 26%（ 13/46）

with statistically significant differences（ χ~2= 0. 205

P = 0. 650）. CONCLUSIONS: Kangfuxin liquid in adjuvant antituberculous chemotherapy for intestinal tuberculosis can significantly reduce the level of inflammatory factors

improve the cellular immune system

and enhance the clinical effects with higher safety.

关键词

康复新液抗结核化疗肠结核炎症因子T淋巴细胞亚群

Keywords

Kangfuxin liquidAnti-tuberculous chemotherapyIntestinal tuberculosisInflammatory factorsT lymphocyte subsets

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of Kangfuxin Liquid Combined with Anti-Tuberculosis Drugs in the Treatment of Intestinal Tuberculosis and Effects on Levels of Vascular Endothelial Growth Factor and Nuclear Factor-κB in Serum and Intestinal Mucosa

Effects of Reduced Glutathione Infusion on Inflammatory Response in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Effects of Budesonide for Inhalation on Ventilator Weaning Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Expression of T Lymphocyte Subsets in Peripheral Blood of Patients with AIDS Complicated with PCP and Its Correlation with Therapeutic Effect of Compound Sulfamethoxazole

Efficacy of Xuanfei Tongluo Formula in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia and Its Effects on Inflammatory Factors, sIgA, hBD2 and CAL

Related Author

ZHAO Weijin

LIU Peiqian

CHEN Qing

GAO Jintan

CHEN Chen

WANG Yang

ZHANG Xiangru

ZHU Bai

Related Institution

Dept.of Pharmacy, Shijiazhuang City Luancheng People’s Hospital

Dept.of Geriatrics, People’s Hospital of Wei County

Dept.of Cardiology, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Pharmacy,the First affiliated Hospital,Xi’an Jiaotong University

⁰